Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Am J Respir Crit Care Med
1 Clin Infect Dis
1 Eur Respir J
4 J Infect Dis
4 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. MEDINA N, Alastruey-Izquierdo A, Mercado D, Bonilla O, et al
    Comparative performance of the laboratory assays used by a diagnostic laboratory hub for opportunistic infections in people living with HIV.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002631.
    PubMed         Abstract available

    Am J Respir Crit Care Med

  2. ESCALANTE P, Wilson JW
    New Diagnostics to Infer Risk in Tuberculosis: Is the Term Latent Tuberculosis Infection Obsolete?
    Am J Respir Crit Care Med. 2021 Feb 17. doi: 10.1164/rccm.202101-0131.

    Clin Infect Dis

  3. ACHARYA MP, Pradeep SP, Murthy VS, Chikkannaiah P, et al
    CD38 +CD27 -TNF-alpha + on Mtb-specific CD4 + T is a robust biomarker for tuberculosis diagnosis.
    Clin Infect Dis. 2021 Feb 19. pii: 6144985. doi: 10.1093.
    PubMed         Abstract available

    Eur Respir J

  4. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.

    J Infect Dis

  5. CLICK ES, Kurbatova E, Alexander H, Dalton TL, et al
    Isoniazid- and Rifampin-Resistance Mutations Associated with Resistance to Second-line Drugs and with Sputum Culture Conversion.
    J Infect Dis. 2020 Jan 31. pii: 5718252. doi: 10.1093.
    PubMed         Abstract available

  6. DUBEY N, Khan MZ, Kumar S, Sharma A, et al
    Mycobacterium tuberculosis PPiA interacts with host integrin receptor to exacerbate disease progression.
    J Infect Dis. 2021 Feb 13. pii: 6134355. doi: 10.1093.
    PubMed         Abstract available

  7. RAO MUVVA J, Ahmed S, Rekha RS, Kalsum S, et al
    Immunomodulatory agents combat multidrug-resistant tuberculosis by improving antimicrobial immunity.
    J Infect Dis. 2021 Feb 19. pii: 6145048. doi: 10.1093.
    PubMed         Abstract available

  8. MUDDE SE, Alsoud RA, van der Meijden A, Upton AM, et al
    Predictive modeling to study the treatment-shortening potential of novel tuberculosis drug regimens, towards bundling of preclinical data.
    J Infect Dis. 2021 Feb 19. pii: 6145049. doi: 10.1093.
    PubMed         Abstract available

    PLoS One

  9. YUEN CM, Millones AK, Puma D, Jimenez J, et al
    Closing delivery gaps in the treatment of tuberculosis infection: Lessons from implementation research in Peru.
    PLoS One. 2021;16:e0247411.
    PubMed         Abstract available

  10. KASSA GM, Merid MW, Muluneh AG, Wolde HF, et al
    Comparing the impact of genotypic based diagnostic algorithm on time to treatment initiation and treatment outcomes among drug-resistant tuberculosis patients in Amhara region, Ethiopia.
    PLoS One. 2021;16:e0246938.
    PubMed         Abstract available

  11. NAZNEEN A, Tarannum S, Chowdhury KIA, Islam MT, et al
    Implementation status of national tuberculosis infection control guidelines in Bangladeshi hospitals.
    PLoS One. 2021;16:e0246923.
    PubMed         Abstract available

  12. EDWARDS BD, Edwards J, Cooper R, Kunimoto D, et al
    Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting.
    PLoS One. 2021;16:e0246993.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.